Frank Cheng is CEO of Caristo Diagnostics. Over the last 20 years he has led multiple digital health companies. Frank previously led two venture-backed companies as CEO and held executive positions with GE, Roche, Hillrom, and Stereotaxis. Prior to Caristo, he was President and Chief Commercial Officer of a diagnostic company with autonomous AI technology that was FDA-cleared, Medicare-reimbursed, supported by a new Category 1 CPT code, and adopted around the world.
Now, with the ability to measure coronary inflammation through AI-enhanced CT scans and to more accurately determine a person's risk of heart attack, we can intervene earlier and more effectively.